Boardroom Alpha
Boardroom Alpha
NSPR · Additional Proxy Materials (DEFA14A) · Filed April 22, 2026

Inspiremd Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 22, 2026
Ticker
NSPR
Accession
0001493152-26-018558
Boardroom Alpha · Filing insights

InspireMD says Proposal 2 is routine, enabling broker voting on uninstructed shares; updates broker-non-vote guidance.

About Inspiremd Inc
Market cap
$47M
1Y TSR
−57.1%
3Y TSR
−20.0%
Board grade
C-
Sector
Healthcare
CEO
Marvin Slosman
Last annual meeting: Jun 3, 2026 · View full Inspiremd Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement
   
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
Definitive Proxy Statement
   
Definitive Additional Materials
   
Soliciting Material Pursuant to §240.14a-12

 

INSPIREMD, INC.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):
 
No fee required.
   
Fee paid previously with preliminary materials.
   
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11

 

 

 

 

 

 

 

InspireMD, Inc.

6303 Waterford District Drive, Suite 215

Miami, Florida 33126

Telephone: (888) 776-6804

 

Supplement to the Proxy Statement Dated April 20, 2026

For the 2026 Annual Meeting of Stockholders of InspireMD, Inc

To be held Wednesday, June 3, 2026

 

This Supplement to the Proxy Statement, dated April 22, 2026 (the “Supplement”), supplements and, to the extent inconsistent therewith, supersedes the below described portions of the definitive proxy statement filed by InspireMD, Inc., a Delaware corporation (the “Company”) with the U.S. Securities and Exchange Commission (the “SEC”) on April 20, 2026 (the “Proxy Statement”) and made available to the Company’s stockholders in connection with the solicitation by the Company’s Board of Directors of proxies to be voted at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) to be held at 10:00 a.m., Eastern Time, on Wednesday, June 3, 2026, and at any postponements or adjournments thereof. Except as described below, this Supplement does not revise, update, or supplement any other information set forth in the Proxy Statement. This Supplement is being furnished in order to provide updated information regarding the ability of brokers to vote uninstructed shares on certain proposals.

 

THE PROXY STATEMENT CONTAINS IMPORTANT INFORMATION AND THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

 

The disclosures in the Proxy Statement under “About the Annual Meeting” with respect to Proposal 2 in the Proxy Statement, which seeks stockholder approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s Common Stock, par value $0.0001 per share, from 150 million to 250 million (“Proposal 2”), are hereby updated to provide that Proposal 2 is a “routine” matter eligible for discretionary voting by brokers and other nominees under New York Stock Exchange (“NYSE”) rules.

 

Pursuant to NYSE rules, if you hold your shares through a broker or other nominee (i.e., in “street name”) and do not instruct such broker or other nominee on how to vote your shares, your broker or other nominee is not permitted to vote your shares in its discretion on “non-routine” matters, but is permitted to vote your shares in its discretion on “routine” matters as determined by NYSE.

 

Accordingly, because Proposal 2 is a “routine” matter, if your shares are held in street name and you do not submit voting instructions, your broker or other nominee can vote your shares on Proposal 2.

 

The answer to the question titled “What is a broker non-vote?” on page 8 of the Proxy Statement is hereby revised in its entirety to read as follows:

 

A broker non-vote occurs when a broker holding shares for a beneficial owner does not vote on a particular proposal because the broker does not have discretionary voting power with respect to that item and has not received voting instructions from the beneficial owner. Your broker does not have discretionary authority to vote your shares with respect to the Director Election Proposal (Proposal 1) or the Adjournment Proposal (Proposal 4) in the absence of specific instructions from you.

 

With respect to the Authorized Shares Proposal (Proposal 2) and the Auditor Reappointment Proposal (Proposal 3), your broker will have the discretion to vote your shares and, therefore, will be able to vote your shares with respect to such proposals even if you do not provide your broker with instructions on that proposal.

 

The second paragraph of the answer to the question titled “How are abstentions and broker non-votes treated?” on page 11 of the Proxy Statement is hereby revised in its entirety to read as follows:

 

Broker non-votes are included in the determination of the number of shares present at the Annual Meeting for determining a quorum at the meeting. Broker non-votes will have no effect upon the election of directors under the Director Election Proposal (Proposal 1), the approval of an amendment to the Company’s Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock under the Authorized Shares Proposal (Proposal 2), the ratification of the reappointment of the independent registered public accounting firm under the Auditor Reappointment Proposal (Proposal 3) or the approval of an adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes to establish a quorum or in favor of proposals 1 through 3 under the Adjournment Proposal (Proposal 4). However, with respect to the approval of an amendment to the Company’s Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock under the Authorized Shares Proposal (Proposal 2) and the ratification of the reappointment of the independent registered public accounting firm under the Auditor Reappointment Proposal (Proposal 3), we expect that there will be only minimal (if any) broker-non-votes because each of those proposals is considered a “routine” matter, and a broker holding shares for a beneficial owner will therefore have discretionary authority to vote those shares for each of those proposals in the absence of voting instructions from the beneficial owner.

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Inspiremd Inc (NSPR)

Reference

Frequently asked questions

When did Inspiremd Inc file this DEFA14A?
Inspiremd Inc (NSPR) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 22, 2026. The accession number assigned by EDGAR is 0001493152-26-018558.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
InspireMD says Proposal 2 is routine, enabling broker voting on uninstructed shares; updates broker-non-vote guidance. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Inspiremd Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Inspiremd Inc has filed under CIK 1433607, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer